glyburide has been researched along with Cardiomyopathies in 2 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen consecutive patients with type 2 diabetes and coronary artery disease entered the study." | 2.70 | Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. ( Avogaro, A; Bagolin, E; Negut, C; Palisi, M; Scognamiglio, R; Tiengo, A; Vigili de Kreutzenberg, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, EA | 1 |
| Guppy, LJ | 1 |
| Scognamiglio, R | 1 |
| Avogaro, A | 1 |
| Vigili de Kreutzenberg, S | 1 |
| Negut, C | 1 |
| Palisi, M | 1 |
| Bagolin, E | 1 |
| Tiengo, A | 1 |
1 trial available for glyburide and Cardiomyopathies
| Article | Year |
|---|---|
Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.
Topics: Cardiomyopathies; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipyridamole; Echocardiography, Str | 2002 |
1 other study available for glyburide and Cardiomyopathies
| Article | Year |
|---|---|
Cardiomyopathic changes in streptozotocin-induced diabetes.
Topics: Adenosine Triphosphatases; Animals; Body Weight; Calcium Channel Blockers; Cardiomyopathies; Cardiot | 1999 |